Huntsman Cancer Institute Shared Resource Showcase

March 15th, 2021

Chat

01:33:42 Neli Ulrich: Can you explain what PSTO is?

01:34:34 DEBRA SORENSON MA: Population Sciences Trials Office. I was hoping Lance would hop in, but I will provide a link.

01:35:26 DEBRA SORENSON MA: https://pulse.utah.edu/site/HCI/Pages/Population-Sciences-Trials-Office.aspx

01:36:45 Manish Kohli: I take it that all databases are 21 CFR part 11 compliant?

01:37:35 Andrew Post: The databases that are designed for clinical trials, yes.

01:37:48 Manish Kohli: Many thnx!

01:38:03 Manish Kohli: CCR as well? Correct?

01:38:15 Lance Lewis: Thanks Deb. Great job. Yes, the Population Sciences Trials Office is a central resource that focuses on trials that are outside of the scope of the Clinical Trials Office, which focuses

01:38:39 Lance Lewis: (Sorry … cut off) on Interventional Treatment drug trials. PSTO focuses on Interventional Non-Treatment trials, Cancer Prevention trials, Observational trials, etc.

01:39:06 Andrew Post: OnCore is, but not CCR.

01:42:57 John Maxwell Loveless: How do you add imaging to animal studies and obtain IACUC approval? How long does it take?

01:44:34 Jeff Yap: There is standard language provided for adding preclinical imaging to existing IACUC protocols. In most cases, it take a week or less to get IACUC approval. Investigators using the Preclinical Research Resource can already use any of the imaging under existing PRR IACUC protocols.

01:45:21 John Maxwell Loveless: Thanks, Jeff!

01:48:43 John Maxwell Loveless: Do you work with syngeneic models for immunotherapy studies?

01:49:29 katemodzelewska: Yes, our cell bank has several models and we are interested in expanding.

01:50:29 John Maxwell Loveless: Can you work with pharma or biotech as part of collaborative projects?

01:51:18 katemodzelewska: Yes. We have several established collaborations, primarily using our PDX models to test novel drugs, those companies are developing.

01:51:47 John Maxwell Loveless: Thanks, Kate.

01:58:13 John Maxwell Loveless: How do I check to see what biospecimens are available in the biobank at a given time?

01:58:58 Chris Fillmore: For simple requests, contact BMP, and for more complex queries we can help you reach out to RISR for a complete query

01:59:00 BINGJIAN FENG: Do you have record if the blood is collected before or after treatment?

01:59:21 Chris Fillmore: Yes, we track clinical data associated with each patient

02:02:44 John Maxwell Loveless: For NanoStrings pre-built panels targeting specific pathways or diseases, what model organisms are they available for and if pre-built panels are not available for a specific model organism are custom panels still an option?

02:05:07 Christy Warby: Do you have established protocols for ctDNA?

02:05:13 John O'Shea: The most extensive catalogue of pre-built panels are available for human and mouse. There are also some panels available for rat, dog and non-human primate. Custom panels are a good option for other model organisms, and we have extensive experience designing and running these panels.

02:06:22 John O'Shea: Yes, we have purification protocols in place and have designed assays to look for specific mutations in cfDNA

02:06:37 Jeffrey M Kenney: Hi All, in the previous presentation, Chris mentioned a summary page for all the Shared Resources, please see the following link. https://pulse.utah.edu/site/HCI/Pages/Shared-Resources.aspx

02:06:37 David Nix: The BSR has established workflows for analyzing ctDNA samples.

02:10:24 John Maxwell Loveless: Your hourly charge back rates are quite low compared to other bioinformatic cores. Are you planning to increase these in the near future?

02:11:39 David Nix: Yes, we will be working with our FAC to increase these rates in late 2021, probably near $75/hr

02:18:01 Angela Snow: How comfortable would you feel about sequencing customer-prepared DNA libraries WITHOUT the Agilent Tapestation QC step if, hypothetically, the Tapestation reagents were backordered for several months?

02:25:39 John Maxwell Loveless: What are appropriate timelines for proposal and investigator-initiated trial preparation, as well as abstract and manuscript preparation?

02:26:20 BENJAMIN HAALAND: It is best to reach out as soon as possible, so that we can provide input on study design.

02:27:22 BENJAMIN HAALAND: If the study design already appropriate ~1 month is a reasonable minimum time for proposals, with a bit more for abstracts.

02:28:26 BENJAMIN HAALAND: For manuscripts, much more time may be needed depending on complexity. Perhaps 2-3 months as a minimum (if the analyses are relatively straightforward).

02:28:40 John Maxwell Loveless: Thanks, Ben

02:30:35 BINGJIAN FENG: Are the slides available somewhere?

02:30:57 Melanie DeJulis: The written summary of the shared resources presented today can be found here: https://pulse.utah.edu/site/HCI/Pages/Shared-Resources.aspx.

02:31:47 Chelsie Smith: Great presentations! How is this format perceived by the group? Any recommendations for a future Shared Resource Showcase?

02:35:41 BINGJIAN FENG: I have a question for Karen UPDB, how difficult is it to share UPDB pedigrees with external institutions. Note that pedigree structure is deemed identifiable data.

02:40:33 BINGJIAN FENG: Thank you Karen!

02:41:03 Melanie DeJulis: Hi Bingjian, thank you for your question about the slides. The recorded presentations will be posted in the near future on Pulse and our shared resources websites https://uofuhealth.utah.edu/huntsman/shared-resources/

02:41:40 BINGJIAN FENG: Thanks Melanie!

02:52:23 Spencer Thomas: This was a GREAT idea and format!

02:52:50 Jessica Moehle: Nice format and I liked the recordings with live Q&A afterward

02:52:58 Angela Snow: Thank you! I have worked at HCI for years, and I was not aware of some of these resources.

02:53:14 Lance Lewis: Great forum. Thanks.